Acadian Asset Management LLC Decreases Stock Holdings in Alignment Healthcare, Inc. $ALHC

Alignment Healthcare (ALHC) experienced mixed institutional trading, with Acadian Asset Management reducing its stake by 12.4% while other funds increased positions, contributing to 86.19% institutional ownership. Analyst sentiment is generally positive, with a "Moderate Buy" average rating and recent price target increases, yet significant insider selling exceeding $122 million in the last 90 days presents a counterpoint. This comes as ALHC reported a Q3 EPS beat of $0.02 against a -$0.01 consensus and 43.5% revenue growth to $993.70 million, though the company remains unprofitable with a negative PE ratio.

Analysis

Alignment Healthcare (ALHC) reported a strong Q3, with earnings per share of $0.02 significantly beating the -$0.01 consensus and revenue reaching $993.70 million, exceeding expectations and representing a 43.5% year-over-year increase. Despite this growth, the company remains unprofitable, reflected in a negative PE ratio of -139.75 and negative net margin of 0.57%. Analyst sentiment is largely positive, with an average "Moderate Buy" rating and an average price target of $19.85, supported by recent upgrades from Wall Street Zen and KeyCorp.

Institutional ownership remains high at 86.19%, though activity is mixed; Acadian Asset Management reduced its stake by 12.4%, selling 46,523 shares, while several other funds like MCF Advisors LLC and Signaturefd LLC substantially increased their positions. A significant counter-signal is the substantial insider selling, totaling over $122 million across 7.59 million shares in the last 90 days, including sales by insider Hyong Kim and Director Joseph S. Konowiecki. This insider activity represents a notable divestment despite the positive earnings surprise.

ALHC's stock opened at $16.77, trading above its 200-day moving average of $15.43 but slightly below its 50-day moving average of $16.97. The company's market capitalization stands at $3.36 billion, with a beta of 1.17 indicating higher volatility than the broader market. The strong revenue growth and positive analyst outlook contrast with the continued unprofitability and substantial insider selling, creating a nuanced investment profile.

Key Decisions for Investors

• Investors should weigh the strong Q3 revenue growth and positive analyst sentiment against the company's persistent unprofitability and the significant insider selling activity, which could signal concerns about future prospects.
• It would be prudent to monitor upcoming earnings reports for sustained profitability improvements and further insider transaction disclosures to gauge management's confidence.
• Consider the high institutional ownership as a potential stabilizing factor, but remain cautious given the mixed signals on long-term value creation.